5-Hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - Opportunities for novel therapeutics to reduce the problems of levodopa therapy

European Journal of Neurology

Volumn 9, Issue SUPPL. 3, 2002, Pages 1-6

  Nicholson, S L ^a   Brotchie, J M ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Williams House   (United Kingdom)

Author keywords

Levodopa; Levodopa induced dyskinesia; Parkinson's disease; Serotonin

Indexed keywords

3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; BROMOCRIPTINE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE; SARIZOTAN; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

BASAL GANGLION; BRAIN REGION; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG METABOLISM; DYSKINESIA; GABAERGIC SYSTEM; HUMAN; NERVE CELL NECROSIS; NERVE PROJECTION; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0036460744     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.9.s3.1.x     Document Type: Review

References (45)

1. Bankson MG, Cunningham KA (2002). Pharmacological studies of the acute effects of (+)-3,4-methylenedioxy-methamphetamine on locomotor activity: Role of 5-HT(1B/1D) and 5-HT(2) receptors. Neuropsychopharmacology 26:40-52.
2. Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152.
3. Bezard E, Brotchie JM, Gross CE (2001). Pathophysiology of levodopa-induced dyskinesia in Parkinson's disease: Opportunities for novel treatments. Nature Rev Neuroscience 2:577-588.
4. Bibbiani F, Oh JD, Chase TN (2001). Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57:1829-1834.
5. Brunner D, Buhot MC, Hen R, Hofer M (1999). Anxiety, motor activation, and maternal-infant interactions in 5-HT1B knockout mice. Behav Neuroscience 113:587-601.
6. Chadha A, Sur C, Atack J, Duty S (2000). The 5-HT(1B) receptor agonist, CP-93129, inhibits [(3)H]-GABA release from rat globus pallidus slices and reverses akinesia following intrapallidal injection in the reserpine-treated rat. Br J Pharmacol 130:1927-1932.
7. De Deurwaèrdere P, Chesselet MF (2000). Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl) piperazine in adult rats. J Neuroscience 20:5170-5178.
8. Di Matteo V, Cacchio M, Di Giulio C, Esposito E (2002). Role of serotonin (2C) receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 71:727-734.
9. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y (1995). Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 45:1855-1858.
10. Filip M, Cunningham KA (2002). Serotonin 5-HT(2C) receptors in nucleus accumbens regulate expression of the hyperlocomotive and discriminative stimulus effects of cocaine. Pharmacol Biochem Behav 71:745-756.
11. Fox SH, Brotchie JM (1996). Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat. European J Pharmacol 301:27-30.
12. Fox SH, Brotchie JM (2000a). 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Movement Disorders 6:1064-1069.
13. Fox SH, Brotchie JM (2000b). 5-HT (2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. European J Pharmacol 398:59-64.
14. Fox SH, Moser B, Brotchie JM (1998). Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151:35-49.
15. Frechilla D, Coberos A, Saldise L et al. (2001). Serotonin 5-HT1A receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39:288-296.
16. Gerber R, Altar CA, Liebman JM (1988). Rotational behavior induced by 8-hydroxy-DPAT, a putative 5-HT-1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl) 94:178-182.
17. Hornykiewicz O (1998). Biochemical aspects of Parkinson's disease. Neurology 51:S2-S9.
18. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A (1994). Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44:77-80.
19. Knobelman DA, Kung HF, Lucki I (2000). Regulation of extracellular concentrations of 5-hydroxytryptamine (5HT) in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors. J Pharmacol Exp Therapeutics 292:1111-1117.
20. Kung M-P, Frederick D, Mu M, Zhuang Z-P, Kung H (1995). 125p-MPPI as a new selective radioligand of serotonin-1A sites in rat brain: In vitro binding and autoradiographic studies. J Pharmacol Exp Therapeutics 272:429-437.
21. Lavoie B, Parent A (1990). Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comparative Neurol 299:1-16.
22. Lees AJ, Stern GM (1981). Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurgery Psychiatry 44:1020-1023.
23. Leopold NA (2000). Risperidone treatment of drug-related psychosis in patients with parkinsonism. Movement Disorders 15:301-304.
24. Levy R, Hazrati LN, Herrero MT et al. (1997). Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states. Neuroscience 76:335-343.
25. Luginger E, Wenning GK, Bosch S, Poewe W (2000). Beneficial effects of amantadine on 1-dopa-induced dyskinesias in Parkinson's disease. Movement Disorders 15:873-878.
26. Maroteaux L, Saudou F, Amlaiky N, Boschert U, Plassat JL, Hen R (1992). Mouse 5-HT1B serotonin receptor: Cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci USA 89:3020-3024.
27. McCreary AC, Bankson MG, Cunningham KA (1999). Pharmacological studies of the acute and chronic effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: Role of 5-hydroxytryptamine (1A) and 5-hydroxytryptamine (1B/1D) receptors. J Pharmacol Exp Therapeutics 290:965-973.
28. McMahon LR, Cunningham KA (1999). Antagonism of 5-hydroxytryptamine(4) receptors attenuates hyperactivity induced by cocaine: Putative role for 5-hydroxytryptamine(4) receptors in the nucleus accumbens shell. J Pharmacol Exp Therapeutics 291:300-307.
29. Messina D, Annesi G, Serra P et al. (2002). Association of the 5-HT6 receptor gene polymorphism C267T with Parkinson's disease. Neurology 58:828-829.
30. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN (1999). Amantadine for levodopa-induced dyskinesias: A 1-year follow-up study. Arch Neurol 56:1383-1386.
31. Pearce RK, Banerji T, Jenner P, Marsden CD (1998). De novo administration of ropinirole and bromocriptine induces less dyskinesia than 1-dopa in the MPTP-treated marmoset. Movement Disorders 13:234-241.
32. Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A (2000). The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurgery Psychiatry 68:589-594.
33. 1A receptor in the rat brain: Correlation with receptor binding. J Neuroscience 12:440-453.
34. Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F (2002). The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol 25:21-24.
35. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484-1491.
36. Rascol A, Guiraud B, Montastruc JL, David J, Clanet M (1979). Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurgery Psychiatry 42: 143-150.
37. Riad M, Garcia S, Watkins KC et al. (2000). Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comparative Neurol 417:181-194.
38. Rick CE, Stanford IM, Lacey MG (1995). Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: Evidence for a direct action mediated by 5-hydroxytryptamine 2C receptors. Neuroscience 69:903-913.
39. Rinne UK (1983). Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurologica Scandanavica 95:19-26.
40. Sari Y, Lefèvre K, Bancila M et al. (1997). Light and electron microscopic immunocytochemical visualization of 5-HT1B receptors in the rat brain. Brain Res 760:281-286.
41. Seedat S, Kesler S, Niehaus DJ, Stein DJ (2000). Pathological gambling behaviour: Emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depression Anxiety 11:185-186.
42. Snow BJ, Macdonald L, Mcauley D, Wallis W (2000). The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study. Clin Neuropharmacol 23:82-85.
43. Stanford IM, Lacey MG (1996). Differential actions of serotonin, mediated by 5-HT1B and 5-HT2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata neurons in vitro. J Neuroscience 16:7566-7573.
44. Stocchi F, Nordera G, Marsden CD (1997). Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 20:95-115.
45. Tomiyama M, Kimura T, Tanaka H et al. (2000). Effects of 8OH-DPAT, a 5-HT1A receptor agonist, on L-dopa-induced dyskinesias in rats with nigrostriatal denervation. Soc for Neuroscience (USA), 10. (Abstract 278).